Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
about
Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample.Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteersAntidepressants in the treatment of neuropathic pain.Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.PharmGKB summary: citalopram pharmacokinetics pathway.Therapeutic drug monitoring of non-tricyclic antidepressant drugs.Aging and clinical pharmacology: implications for antidepressants.Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.Influence of chronic administration of antidepressant drugs on mRNA for galanin, galanin receptors, and tyrosine hydroxylase in catecholaminergic and serotonergic cell-body regions in rat brain.Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neuronsPharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications.Adherence of antidepressants during pregnancy: MEMS compared with three other methods.Gender differences in antidepressant drug response.Sex differences in pharmacokinetics of antidepressants.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder.CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.Adult respiratory distress syndrome and renal failure associated with citalopram overdose.Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.[Correlation between dose/plasma concentration and assessment of hepatic and renal changes in Wistar rats treated with the ROM scheme].Role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus?Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients.
P2860
Q30487373-D346EC45-3BAC-40DF-95A0-09ABFB572A70Q31121208-BE3B2041-6842-473A-820C-EB8EFABF890CQ33326612-8D51018B-80FC-45CD-805A-D7FC38658F4CQ34019331-DBE37107-DE8F-4C1F-8387-EBACC4C585CBQ34420689-80414F40-6860-4A34-B47B-3C18EA23DF81Q35106246-B08A172B-A6AC-459C-8CBF-5A43459B76C5Q35236618-B08BA189-314F-44FA-A82E-41A91864BA75Q35952370-E222E321-FC37-46E8-B4AC-EE95A429F438Q35970340-78EA4044-40C4-41BC-B659-43259AE3AC9CQ36261418-DFCFAB47-A999-465D-B1CC-55FC8CDA2693Q36536465-60B35C29-0147-4A86-B9A3-EC30D6ED92BEQ37137501-C888CBBE-FC03-44B5-8B5F-DDA931A9172EQ37236791-E771BF92-82B3-4765-92E6-F022AE4C3F86Q37618221-47340B3B-52BE-4300-B3B4-DE7D021DFBC0Q37634873-6E79A740-5570-413C-AA12-8288906DCF6AQ37806757-E5F32A3A-366E-4903-864E-0A3C12B11D2EQ37824711-F17B6767-A43F-498B-825F-862281C238C6Q38123516-725439D3-4321-401A-8D46-960251DC60C0Q42674455-AEEAABC6-BE61-4676-8403-5DB4AEEF6DE6Q42788954-46258DEC-F7BE-4B45-B41E-CC21488F9FB0Q44402391-E1FD76A1-D2DF-490D-8BB8-263628D8C124Q45117146-FB721399-7D9A-448E-A626-A96A19ACDEC0Q46430990-710A854B-19B8-4DDE-BB59-5EDC99E9768FQ47237324-ED43D030-BEB0-4CFD-A6F6-E2646749A408Q50475979-8676880B-8620-4A12-BCEB-7BCD82A9EB06
P2860
Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Is therapeutic drug monitoring ...... serotonin reuptake inhibitors?
@ast
Is therapeutic drug monitoring ...... serotonin reuptake inhibitors?
@en
type
label
Is therapeutic drug monitoring ...... serotonin reuptake inhibitors?
@ast
Is therapeutic drug monitoring ...... serotonin reuptake inhibitors?
@en
prefLabel
Is therapeutic drug monitoring ...... serotonin reuptake inhibitors?
@ast
Is therapeutic drug monitoring ...... serotonin reuptake inhibitors?
@en
P1476
Is therapeutic drug monitoring ...... serotonin reuptake inhibitors?
@en
P2093
Rasmussen BB
P304
P356
10.1097/00007691-200004000-00001
P577
2000-04-01T00:00:00Z